- Home
- MLGO vs TCRX Comparison
MLGO vs TCRX Comparison
Compare MLGO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLGO
- TCRX
- Stock Information
- Founded
- MLGO 2018
- TCRX 2018
- Country
- MLGO China
- TCRX United States
- Employees
- MLGO N/A
- TCRX N/A
- Industry
- MLGO EDP Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MLGO Technology
- TCRX Health Care
- Exchange
- MLGO Nasdaq
- TCRX Nasdaq
- Market Cap
- MLGO 99.2M
- TCRX 91.7M
- IPO Year
- MLGO N/A
- TCRX 2021
- Fundamental
- Price
- MLGO $10.01
- TCRX $1.72
- Analyst Decision
- MLGO
- TCRX Strong Buy
- Analyst Count
- MLGO 0
- TCRX 5
- Target Price
- MLGO N/A
- TCRX $9.40
- AVG Volume (30 Days)
- MLGO 331.9K
- TCRX 218.2K
- Earning Date
- MLGO 12-16-2025
- TCRX 11-11-2025
- Dividend Yield
- MLGO N/A
- TCRX N/A
- EPS Growth
- MLGO N/A
- TCRX N/A
- EPS
- MLGO 4.04
- TCRX N/A
- Revenue
- MLGO $61,302,336.00
- TCRX $6,961,000.00
- Revenue This Year
- MLGO N/A
- TCRX $255.18
- Revenue Next Year
- MLGO N/A
- TCRX N/A
- P/E Ratio
- MLGO $2.26
- TCRX N/A
- Revenue Growth
- MLGO N/A
- TCRX N/A
- 52 Week Low
- MLGO $7.82
- TCRX $1.02
- 52 Week High
- MLGO $972.00
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- MLGO 50.71
- TCRX 43.84
- Support Level
- MLGO $8.25
- TCRX $1.73
- Resistance Level
- MLGO $9.66
- TCRX $1.96
- Average True Range (ATR)
- MLGO 0.65
- TCRX 0.11
- MACD
- MLGO 0.52
- TCRX -0.02
- Stochastic Oscillator
- MLGO 73.49
- TCRX 22.58
About MLGO MicroAlgo Inc.
MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.